



Appendix 37 - PEDIATRIC B-CELL LYMPHOMA

Approved settings/ treatment line	Protocols	Drugs in abbreviation	Evidence level
Group A	POG 9219 Regimen.	cyclophosphamide, doxorubicin, vincristine, prednisone, hydrocortisone IT, mtx IT, Cytarabine IT	Category 2A
	FAB/LMB96 Regimen A.	cyclophosphamide, doxorubicin, vincristine, prednisone	Category 2A
Group B (Low-risk)	COG ANHL 1131 Regimen B ± Rituximab	Cyclophosphamide, Vincristine, prednisone, MTX IT, Hydrocortisone IT, Rituximab, doxorubicin, Methotrexate, Leucovorin, Cytarabine, Cytarabine IT	Category 2A, Low & high risk
Group B (High-risk)	POG 9219 Regimen.	cyclophosphamide, doxorubicin, vincristine, prednisone, hydrocortisone IT, mtx IT, Cytarabine IT	Category 2A, Low risk
Group C (CNS-ve)	COG ANHL 1131 Regimen C1 + Rituximab	Cyclophosphamide, Vincristine, prednisone, MTX IT, Hydrocortisone IT, Rituximab, doxorubicin, Methotrexate, Leucovorin, Cytarabine, Cytarabine IT	Category 2A
Group C (CNS +ve)	COG ANHL 1131 Regimen C3 + Rituximab	Cyclophosphamide, Vincristine, prednisone, MTX IT, Hydrocortisone IT, Rituximab, doxorubicin, HD Methotrexate, Leucovorin, Cytarabine, Cytarabine IT	Category 2A
Relapsed	R-CYVE	Rituximab, cytarabine, HD Cytarabine, etoposide, MTX IT, Hydrocortisone IT	Category 2A
	R-ICE	Rituximab, carboplatin, ifosfamide, Etoposide	Category 2A